Coronavirus Thread: Worldwide Pandemic

Payday23

Superstar
Joined
Nov 20, 2014
Messages
14,975
Reputation
1,551
Daps
55,947
1tyexQG.png


Vaccine supplies to the UK could be threatened after Brussels threatened to block exports of the Pfizer vaccine amid plans to reject the AstraZeneca vaccine in Germany for over-65s amid claims it is only for eight per cent of pensioners.

Concerns over vaccine supply on the continent have prompted the European Union to tell pharmaceutical companies they can only export to Britain with explicit permission from the bloc.

It comes as AstraZeneca announced it could not meet the demand of a £300m vaccine deal it made with the EU - and cut the number of vaccines it aimed to deliver by the end of March from 80million to 31million.

Amid concerns of a vaccine shortage on the continent, EU Health commissioner Stella Kyriakides last night warned: 'The European Union will take any action required to protect its citizens and rights.'

She added: 'In the future, all companies producing vaccines against COVID-19 in the EU will have to provide early notification whenever they want to export vaccines to third countries.'

The UK is expecting to receive nearly 3.5million Pfizer doses within the next three weeks.

Last night it was revealed the EU's vaccine regulator is set to reject the UK's Oxford Covid jab for over-65s, according to reports in Germany.

German federal chiefs expect the jab to be just '8 per cent effective' in people over 65 years of age, the newspapers Bild and Handelsblatt reported.

The papers report how German officials fear that EU medicine regulator, the European Medicines Agency (EMA), may not approve the Oxford vaccine for those aged over 65.


The row comes amid a weekend of protests over the tightening of lockdown rules in countries such as Denmark and the Netherlands.

In a statement about tonight's reports in the German press, AstraZeneca said: 'Reports that the AstraZeneca/Oxford vaccine efficacy is as low as 8 per cent in adults over 65 are absolutely incorrect.'

AstraZeneca furiously deny reports in German media over '8% efficacy' | Daily Mail Online

coli #wait-and-see-gang :sas2:
8% !?!

:mjlol:
 

null

...
Joined
Nov 12, 2014
Messages
29,904
Reputation
5,169
Daps
47,271
Reppin
UK, DE, GY, DMV

wait-and-see innit as it might be german/brexit postiuring:ehh: but it is in handelsblatt so it's not tabloid talk. it's written as a criticism of the german vaccine strategy as well, rather than the brits or vaccine itself.

Berlin, Düsseldorf, Brüssel Nach dem umstrittenen Impfstart in Deutschland setzte die Bundesregierung große Hoffnungen in die Zulassung des Vakzins von Astra-Zeneca: Das Präparat des britisch-schwedischen Konzerns soll die RNA-Vakzine von Biontech und Moderna ergänzen und den Weg in die zweite Impfphase ebnen, in der sich die Menschen auch bei den Hausärzten impfen lassen können.

Doch der Impfstoff von Astra-Zeneca, der anders als die RNA-Mittel keine extremen Minusgrade bei der Lagerung benötigt, könnte ausgerechnet für die Corona-gefährdeten Senioren ungeeignet sein: Nach Informationen des Handelsblatts aus Koalitionskreisen rechnet die Bundesregierung nur mit einer Wirksamkeit von acht Prozent bei den über 65-Jährigen. Dass dieser Impfstoff, für den die EU noch in dieser Woche die Zulassung erteilen könnte, nicht an die über 90 Prozent liegende Wirksamkeit der RNA-Vakzine heranreicht, war befürchtet worden. Die extrem geringe Wirksamkeit bei Senioren stellt indes einen Rückschlag für die Berliner Impfstrategie dar.

Astra-Zeneca: Corona-Impfstoff wirkt wohl kaum bei Senioren

also as one breh mentioned a couple of weeks ago, the way they assessed who was infected during some of these trials might also raise questions with some.
 

jj23

Veteran
Supporter
Joined
Nov 26, 2016
Messages
24,941
Reputation
5,876
Daps
114,556

merklman

All Star
Joined
Jun 17, 2012
Messages
2,998
Reputation
65
Daps
3,422
Reppin
N17
wait-and-see innit as it might be german/brexit postiuring:ehh: but it is in handelsblatt so it's not tabloid talk. it's written as a criticism of the german vaccine strategy as well, rather than the brits or vaccine itself.

Berlin, Düsseldorf, Brüssel Nach dem umstrittenen Impfstart in Deutschland setzte die Bundesregierung große Hoffnungen in die Zulassung des Vakzins von Astra-Zeneca: Das Präparat des britisch-schwedischen Konzerns soll die RNA-Vakzine von Biontech und Moderna ergänzen und den Weg in die zweite Impfphase ebnen, in der sich die Menschen auch bei den Hausärzten impfen lassen können.

Doch der Impfstoff von Astra-Zeneca, der anders als die RNA-Mittel keine extremen Minusgrade bei der Lagerung benötigt, könnte ausgerechnet für die Corona-gefährdeten Senioren ungeeignet sein: Nach Informationen des Handelsblatts aus Koalitionskreisen rechnet die Bundesregierung nur mit einer Wirksamkeit von acht Prozent bei den über 65-Jährigen. Dass dieser Impfstoff, für den die EU noch in dieser Woche die Zulassung erteilen könnte, nicht an die über 90 Prozent liegende Wirksamkeit der RNA-Vakzine heranreicht, war befürchtet worden. Die extrem geringe Wirksamkeit bei Senioren stellt indes einen Rückschlag für die Berliner Impfstrategie dar.

Astra-Zeneca: Corona-Impfstoff wirkt wohl kaum bei Senioren

also as one breh mentioned a couple of weeks ago, the way they assessed who was infected during some of these trials might also raise questions with some
.

Do you have anymore info on the bolded?
 

phcitywarrior

Superstar
Supporter
Joined
Nov 19, 2016
Messages
13,511
Reputation
4,690
Daps
32,722
Reppin
Naija / DMV
I’m looking at the NYTimes Covid tracker and there’s a noticeable drop in no. of cases and deaths. About 1.8K deaths as of yesterday. A few weeks back we were at almost 4K a day and rising.

To my knowledge, nothing material has changed in the past two weeks concerning safety measures put in place. Only thing that has changed is the sitting president...

These numbers are looking funny in the light :patrice:
 
Top